RxDoctor Payments Data

Ramsey Ulrich, MD

Internal Medicine · Ventura, CANPI 1215091293

Payments from drug & device makers

$1,143in general payments, 2019–2025

Across 48 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$334
  • Amgen$126
  • Exact Sciences$112
  • Lilly USA, LLC$68
  • Gilead$58
  • Phadia US Inc.$49
  • plus $396 from 13 others

What the payments were for

  • Food & beverage$1,04692%
  • Education$978%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,143 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$146,498
Medicare patients
243
Services billed
1,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$50,580
OzempicSemaglutide48$49,006
XareltoRivaroxaban35$42,370
JardianceEmpagliflozin34$42,301
JanuviaSitagliptin Phosphate24$30,576
TrulicityDulaglutide15$24,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$23,000
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,689
Atorvastatin Calcium353$3,402
Methenamine Hippurate31$3,050
Testosterone12$2,929
Amlodipine Besylate306$2,458
Losartan Potassium150$2,199
Levothyroxine Sodium164$2,134
Gabapentin105$2,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$50,58049 claims
Novo NordiskOzempic$334$49,00648 claims
Boehringer IngelheimJardiance$44$42,30134 claims
Lilly USA, LLCTrulicity$68$24,08615 claims
GSKTrelegy Ellipta$33$23,00023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →